OTUB1 knockdown promotes apoptosis in melanoma cells by upregulating TRAIL expression
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Melanoma, the most serious type of skin cancer, exhibits ahigh risk of metastasis. Although chemotherapeutic treatmentfor metastatic melanoma improves disease outcome and patientsurvival, some patients exhibit resistance or toxicity to the drugtreatment regime. OTUB1 is a deubiquitinating enzyme overexpressedin several cancers. In this study, we investigated theeffects of inhibiting OTUB1 expression on melanoma-cell proliferationand viability and identified the underlying molecularmechanism of action of OTUB1. We did endogenous OTUB1knockdown in melanoma cells using short interfering RNA,and assessed the resulting phenotypes via MTT assays, Westernblotting, and cell-cycle analysis. We identified differentiallyexpressed genes between OTUB1-knockdown cells and controlcells using RNA sequencing and confirmed them via Westernblotting and reverse transcription polymerase chain reaction. Furthermore, we investigated the involvement of apoptotic andcell survival signaling pathways upon OTUB1 depletion. OTUB1depletion in melanoma cells decreased cell viability and causedsimultaneous accumulation of cells in the sub-G1 phase, indicatingan increase in the apoptotic-cell population. RNA sequencingof OTUB1-knockdown cells revealed an increase in thelevels of the apoptosis-inducing protein TRAIL. Additionally,OTUB1-knockdown cells exhibited increased sensitivity toPLX4032, a BRAF inhibitor, implying that OTUB1 and BRAFact collectively in regulating apoptosis. Taken together, ourfindings show that OTUB1 induces apoptosis of melanomacells in vitro, likely by upregulating TRAIL, and suggest thatapproaches targeting OTUB1 can be developed to provide noveltherapeutic strategies for treating melanoma.
Abstract
Melanoma, the most serious type of skin cancer, exhibits ahigh risk of metastasis. Although chemotherapeutic treatmentfor metastatic melanoma improves disease outcome and patientsurvival, some patients exhibit resistance or toxicity to the drugtreatment regime. OTUB1 is a deubiquitinating enzyme overexpressedin several cancers. In this study, we investigated theeffects of inhibiting OTUB1 expression on melanoma-cell proliferationand viability and identified the underlying molecularmechanism of action of OTUB1. We did endogenous OTUB1knockdown in melanoma cells using short interfering RNA,and assessed the resulting phenotypes via MTT assays, Westernblotting, and cell-cycle analysis. We identified differentiallyexpressed genes between OTUB1-knockdown cells and controlcells using RNA sequencing and confirmed them via Westernblotting and reverse transcription polymerase chain reaction. Furthermore, we investigated the involvement of apoptotic andcell survival signaling pathways upon OTUB1 depletion. OTUB1depletion in melanoma cells decreased cell viability and causedsimultaneous accumulation of cells in the sub-G1 phase, indicatingan increase in the apoptotic-cell population. RNA sequencingof OTUB1-knockdown cells revealed an increase in thelevels of the apoptosis-inducing protein TRAIL. Additionally,OTUB1-knockdown cells exhibited increased sensitivity toPLX4032, a BRAF inhibitor, implying that OTUB1 and BRAFact collectively in regulating apoptosis. Taken together, ourfindings show that OTUB1 induces apoptosis of melanomacells in vitro, likely by upregulating TRAIL, and suggest thatapproaches targeting OTUB1 can be developed to provide noveltherapeutic strategies for treating melanoma.
참고문헌 (32)
- Rigel DS, "The incidence of malignant melanoma in the United States : issues as we approach the 21st century", J Am Acad Dermatol, 34, pp.839~847 (1996)
- D’Orazio J, "UV radiation and the skin", Int J Mol Sci, 14, pp.12222~12248 (2013)
- Laikova KV, "Advances in the understanding of skin cancer : ultraviolet radiation, mutations, and antisense oligonucleotides as anticancer drugs", Molecules, 24, pp.1516~ (2019)
- Domingues B, "Melanoma treatment in review", Immunotargets Ther, 7, pp.35~49 (2018)
- Shan TL, "Partial molecular cloning, characterization, and analysis of the subcellular localization and expression patterns of the porcine OTUB1gene", Mol Biol Rep, 36, pp.1573~1577 (2009)
- Nakada S, "Non-canonical inhibition of DNA damage-dependent ubiquitination by OTUB1", Nature, 466, pp.941~946 (2010)
- Juang YC, "OTUB1co-opts Lys48-linked ubiquitin recognition to suppress E2enzyme function", Mol Cell, 45, pp.384~397 (2012)
- Baietti MF, "OTUB1 triggers lung cancer development by inhibiting RAS monoubiquitination", EMBO Mol Med, 8, pp.288~303 (2016)
- Zhou Y, "OTUB1 promotes metastasis and serves as a marker of poor prognosis in colorectal cancer", Mol Cancer, 13, pp.258~ (2014)
- Iglesias-Gato D, "OTUB1de-ubiquitinating enzyme promotes prostate cancer cell invasion in vitro and tumorigenesis in vivo", Mol Cancer, 14, pp.8~ (2015)
- Karunarathna U, "OTUB1inhibits the ubiquitination and degradation of FOXM1 in breast cancer and epirubicin resistance", Oncogene, 35, pp.1433~1444 (2016)
- Weng W, "OTUB1 promotes tumor invasion and predicts a poor prognosis in gastric adenocarcinoma", Am J Transl Res, 8, pp.2234~2244 (2016)
- Ni Q, "Expression of OTUB1 in hepatocellular carcinoma and its effects on HCC cell migration and invasion", Acta Biochim Biophys Sin (Shanghai)., 49, pp.680~688 (2017)
- Zhou H, "OTUB1 promotes esophageal squamous cell carcinoma metastasis through modulating Snail stability", Oncogene, 37, pp.3356~3368 (2018)
- Xu L, "Silencing of OTUB1 inhibits migration of human glioma cells in vitro", Neuropathology, 37, pp.217~226 (2017)
- Schneider P, "TRAIL receptors 1(DR4)and 2(DR5)signal FADD-dependent apoptosis and activate NF-kappaB", Immunity, 7, pp.831~836 (1997)
- Wang S, "TRAIL and apoptosis induction by TNF-family death receptors", Oncogene, 22, pp.8628~8633 (2003)
- Kurbanov BM, "Efficient TRAIL-R1", DR4-mediated apoptosis in melanoma cells by tumor necrosis factor-related apoptosis-inducing ligand(TRAIL), 2005, pp.125, 1010~1019
- Ohtsuka T, "Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK", p38 and mitochondrial death pathway, 2003, pp.22, 2034~2044
- Kim EY, "CAPE promotes TRAILinduced apoptosis through the upregulation of TRAIL receptors via activation of p38 and suppression of JNK in SK-Hep1 hepatocellular carcinoma cells", Int J Oncol, 43, pp.1291~1300 (2013)
- Zhang XD, "Relation of TNF-related apoptosis-inducing ligand(TRAIL)receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma", Cancer Res, 59, pp.2747~2753 (1999)
- Herhaus L, "OTUB1enhances TGFbeta signalling by inhibiting the ubiquitylation and degradation of active SMAD2", 3, 2013, pp.4, 2519~
- Zhou K, "OTUB1-mediated deubiquitination of FOXM1 up-regulates ECT-2 to promote tumor progression in renal cell carcinoma", Cell Biosci, 10, pp.50~ (2020)
- Xu Y, "Targeting the Otub1", c-Maf axis for the treatment of multiple myeloma, 2021, pp.137, 1478~1490
- Sun T, "Inhibition of the Otub1", c-Maf axis by the herbal acevaltrate induces myeloma cell apoptosis, 2021, pp.19, 24~
- Koschel J, "OTUB1 prevents lethal hepatocyte necroptosis through stabilization of c-IAP1during murine liver inflammation", Cell Death Differ, 28, pp.2257~2275 (2021)
- Goncharov T, "OTUB1 modulates c-IAP1 stability to regulate signalling pathways", EMBO J, 32, pp.1103~1114 (2013)
- Wang Y, "OTUB1-catalyzed deubiquitination of FOXM1 facilitates tumor progression and predicts a poor prognosis in ovarian cancer", Oncotarget, 7, pp.36681~36697 (2016)
- Zhou X, "The deubiquitinase Otub1 controls the activation of CD8(+)T cells and NK cells by regulating IL-15-mediated priming", Nat Immunol, 20, pp.879~889 (2019)
- Massa RC, "Targeting the MAPK pathway in advanced BRAF wild-type melanoma", Ann Oncol, 30, pp.503~505 (2019)
- Cheng Y, "Targeting MAPK pathway in melanoma therapy", Cancer Metastasis Rev, 32, pp.567~584 (2013)
- Mandala M, "Targeting BRAF in melanoma : biological and clinical challenges", Crit Rev Oncol Hematol, 87, pp.239~255 (2013)